5 August 2020: The Board of UDG Healthcare plc, a leading international healthcare services provider, is pleased to announce the appointment of Shane Cooke, an independent Non-Executive Director of the Company, as Chair of UDG Healthcare plc with effect from 1 October 2020.
Shane will succeed Peter Gray, who retires from the Board on 30 September 2020 after more than eight years as Chair and 15 years as a Director of the Company. The Company announced Peter’s intention to retire from the Board in its 2019 Annual Report, published in December 2019.
Shane joined the UDG Healthcare plc Board on 1 February 2019 and was later appointed Chair of the Risk, Investment and Financing Committee on 28 January 2020. He is currently a Non-Executive Director of NASDAQ-listed Alkermes plc, having previously held the position of President from September 2011 until his retirement in 2018. Prior to this, Shane spent over 10 years as Chief Financial Officer of Elan Corporation plc and from 2007 he was also Head of Elan Drug Technologies. Prior to Elan he held the role of Chief Executive Officer of Pembroke Capital Ltd., an aviation leasing company of which he was a founder. Shane currently also currently serves as a Non-Executive Director on the Board of Prothena Corporation plc, and of Endo International plc, both publicly quoted companies.
Commenting on the appointment, Peter Gray, Chair of UDG Healthcare plc, said:
"Following a robust and thorough selection process led by our Senior Independent Director, Myles Lee, I am delighted to be handing over to Shane in October. His breadth of experience, particularly in the US healthcare market, will be a great asset in guiding the board of UDG as it continues to chart its strategic course."
No further information is required to be disclosed pursuant to Listing Rule 9.6.11R.
For further information, please contact:
General Counsel & Company Secretary
Lisa Kavanagh / Eavan Gannon
About UDG Healthcare plc:
UDG Healthcare plc (LON: UDG) is a FTSE 250 global leader in the healthcare advisory, communications, commercial, clinical and packaging services industries. UDG employs 9,000 people across operations in 29 countries, delivering services in over 50 countries.
Operating across two divisions, Ashfield and Sharp, UDG provides outsourced services which enable over 300 healthcare companies from large pharmaceutical to small biotech to bring their products to market.
Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across three business areas: Advisory, Communications and Commercial & Clinical. The division focuses on supporting patients to access and adhere to their medications and educating and communicating effectively with healthcare professionals and patients on these products at all stages of the product life cycle. Ashfield provides strategic consulting, advisory services, patient solutions, scientific and creative communications, PR, on-demand advertising services, field and contact centre sales teams, and medical information and event management services.
Sharp is a global leader in contract commercial packaging, clinical, manufacturing and technology services for the pharmaceutical and biotechnology industries, operating from eight state-of-the-art facilities in the US and Europe.
For more information, please go to: www.udghealthcare.com